Alnylam Pharmaceuticals Inc. to Post FY2020 Earnings of $3.98 Per Share, FBR & Co Forecasts (ALNY)
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) – Investment analysts at FBR & Co lowered their FY2020 EPS estimates for shares of Alnylam Pharmaceuticals in a research note issued on Thursday. FBR & Co analyst C. James now anticipates that the firm will post earnings per share of $3.98 for the year, down from their previous forecast of $4.40. FBR & Co has a “Buy” rating and a $100.00 price objective on the stock.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Wednesday, November 2nd. The biopharmaceutical company reported ($1.21) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.14) by $0.07. Alnylam Pharmaceuticals had a negative net margin of 1,041.16% and a negative return on equity of 33.97%. The business earned $13.70 million during the quarter, compared to the consensus estimate of $9.14 million. During the same quarter in the prior year, the firm earned ($0.91) EPS. The business’s revenue was up 116.7% on a year-over-year basis.
Other analysts have also recently issued research reports about the company. Needham & Company LLC reissued a “buy” rating and set a $152.00 price objective on shares of Alnylam Pharmaceuticals in a report on Monday, July 25th. Jefferies Group dropped their price objective on Alnylam Pharmaceuticals from $86.00 to $58.00 and set a “buy” rating on the stock in a report on Thursday, October 6th. JPMorgan Chase & Co. increased their price objective on Alnylam Pharmaceuticals from $80.00 to $83.00 and gave the stock an “overweight” rating in a report on Friday, August 5th. Stifel Nicolaus lowered their price target on Alnylam Pharmaceuticals from $68.00 to $36.00 and set a “hold” rating on the stock in a report on Thursday, October 6th. Finally, Barclays PLC reaffirmed a “hold” rating and issued a $50.00 price target on shares of Alnylam Pharmaceuticals in a report on Thursday, November 3rd. Eight investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Alnylam Pharmaceuticals has an average rating of “Buy” and an average target price of $68.63.
Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 45.975 on Friday. The company’s market cap is $3.95 billion. The firm has a 50-day moving average price of $41.88 and a 200-day moving average price of $60.21. Alnylam Pharmaceuticals has a 52-week low of $31.38 and a 52-week high of $109.10.
Several large investors have recently modified their holdings of the company. Bank of Montreal Can acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth $193,000. Meeder Asset Management Inc. acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth $175,000. IBM Retirement Fund raised its stake in shares of Alnylam Pharmaceuticals by 1.0% in the second quarter. IBM Retirement Fund now owns 7,559 shares of the biopharmaceutical company’s stock worth $419,000 after buying an additional 76 shares in the last quarter. Nisa Investment Advisors LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth $128,000. Finally, BNP Paribas Arbitrage SA raised its stake in shares of Alnylam Pharmaceuticals by 24.0% in the second quarter. BNP Paribas Arbitrage SA now owns 11,126 shares of the biopharmaceutical company’s stock worth $617,000 after buying an additional 2,156 shares in the last quarter. Hedge funds and other institutional investors own 85.20% of the company’s stock.
In other Alnylam Pharmaceuticals news, Director David E. I. Pyott acquired 27,900 shares of the business’s stock in a transaction dated Thursday, October 13th. The shares were purchased at an average cost of $37.00 per share, for a total transaction of $1,032,300.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 4.00% of the stock is owned by insiders.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Receive News & Stock Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.